We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Ergomed Plc | LSE:ERGO | London | Ordinary Share | GB00BN7ZCY67 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 1,346.00 | - | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
07/10/2019 08:50 | steady buying this morning | mfhmfh | |
27/9/2019 09:44 | great company... share price back to 330p soon. IMHO. | mfhmfh | |
27/9/2019 07:09 | Ergomed PLC reports strong order book and significant new business wins | piedro | |
25/9/2019 11:32 | Plenty of board changes Hopefully all for the best Interims: - Revenue £35.2m (up 36.8%) - Adjusted EBITDA £6.5m vs £0.0m in H1 2018 - Backlog £118.3m (up 26.9%) repeated ad infinitum Is that due to the nature of the profession, data medical data ... or something else? | piedro | |
23/8/2019 12:29 | Cherio from the States We see another new 52 Wk high? Anything driving this that you guys are aware of? Please read about the Ergo/CVM connection here: | ih_198062 | |
23/8/2019 11:36 | Dr. Eghosa Olaolu Imasogie joins PrimeVigilance as Chief Medical Officer PUBLISHED 22 AUGUST 2019. | piedro | |
23/8/2019 11:20 | I never bought this stock or indeed PRSM when I should have done...ffs | mirabeau | |
23/8/2019 11:15 | solid buys coming in today | mfhmfh | |
13/8/2019 15:14 | Courtesy of sushifishman, Cel-Sci published an updated fact sheet on 9th August which shows that they are still waiting for 298 events (deaths) in their ongoing Multikine phase III trial. The head & neck cancer trial completed recruitment with its 928th patient in September 2016 and is continuing to monitor survival. The trial will end when 298 events have occurred and that was expected to happen in 2018 so the fact that they haven't yet reached that threshold may be promising. | bermudashorts | |
27/7/2019 09:19 | Of course we don’t actually know that Fullbrook Thorpe are retaining their remaining shares as they are now below the 3% level so they don’t have to report any further sales. I was wondering where all these shares recently on the market were coming from and now we know (at least in part). But clearly the three new recruitments are a VERY impressive list of people and Barfield’s interview was excellent. I suspect that a sizeable fundraising will happen shortly as they seek a war chest for acquisitions. Barfield was a bit cagey about acquisitions, which made me believe that they are very much on the agenda. I’m extremely bullish. | ih_433513 | |
27/7/2019 08:58 | jamtomorrow, Yes, you're correct re. Fullbrook Thorpe, original TR1 is below. They crossed the notification threshold in May 2016 but didn't notify until November 2016. They would have bought at around 140p so a pretty good return. It's not at all surprising to see some profit taking from institutions and reassuring to see them retaining large positions. | bermudashorts | |
27/7/2019 08:41 | Think same applied to Gresham House's TR1 - haven't gone back to check but think it was a reduction rather than a new position. Have taken my eye off the ball with Ergomed so not 100% sure of previous major holdings but seem to remember Gresham House having a position. | bermudashorts | |
27/7/2019 07:39 | I’ve just seen this hxxps://www.marketsc Fullbrook Thorpe used to own 3.17% of Ergomed so this announcement is a reduction in their holding. They clearly don’t know how to complete these TR-1 forms properly! | ih_433513 | |
27/7/2019 07:19 | Maybe there’s the connection. Peter George was CEO of Clinigen and he is a director of Ergomed. Perhaps George and Leaver are acting in concert. Peter George holds 1.74% of Ergomed so if they are in concert they own more than 3% hence the announcement. | ih_433513 | |
27/7/2019 07:04 | >>>>Jamt Don't know for sure, but the main man behind Fuller Thorpe Investments is Andrew Leaver, founder of Clinigen (where he still retains 3%) | timbo003 | |
26/7/2019 20:59 | Why did Fullbrook Thorpe declare their holding when it’s less than 3%? Perhaps they are in concert with someone else or connected with a director, neither of which was declared. Interesting though. | ih_433513 | |
26/7/2019 17:09 | Another larger investment in Ergo. . Fullbrook Thorpe Investments LLP adds 1.2M shares. hxxp://www.share-tal | ih_198062 | |
26/7/2019 07:23 | Piedro, lol sorry, forgot that ADVFN automatically deletes proactive links. mfhmfh - thanks | bermudashorts | |
25/7/2019 16:17 | B.Shorts - a link please | piedro | |
25/7/2019 12:51 | Impressive interview with new CFO Richard Barfield [...] | bermudashorts | |
23/7/2019 15:07 | North Atlantic Smaller Companies Investment Trust PLC adds another 600K per the RNS just filed | ih_198062 | |
22/7/2019 14:32 | really big buys | mfhmfh | |
22/7/2019 13:23 | Big buys coming in now | epicsurf |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions